Chronic Myelogenous Leukemia (CML)

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Cord Blood Transplant in Adults With Blood Cancers

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Nilotinib, for Patients With CML-CP or CML-AP

Phase I Study of Milatuzumab for Graft Versus Host Disease

Unrelated Umbilical Cord Blood (UBC)Transplantation

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation